Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.  Inclusion Criteria:  Documented chronic (≥3 months' duration), non-radicular spine pain  Exclusion Criteria:  Unwilling/unable to refrain from cannabis use (medical or recreational) for 14 days prior to Baseline Visit and throughout the study (other than study drug). This includes whole plant inhalation, edibles, extracts, and topicals.  Co-morbid cancer-related pain condition  Neuropathic Pain  A co-morbid pain condition that is of greater severity than the patient's spine pain  Spine or other major surgery within the 3 months prior to enrollment  Planned surgery or procedural intervention during the study period  Allergy or adverse reaction to cannabis  Current or historical substance use disorder  Current or historical alcohol use disorder  Current or prior cannabis abuse/dependence  Positive result for use of amphetamine/methamphetamine, barbiturates, benzodiazepines, cocaine, phencyclidine (PCP), ecstasy (MDMA), as detected on urine screen  Current use of valproate, clobazam, clopidogrel, warfarin, barbiturates, benzodiazepines  Prior adverse reaction to cannabis exposure (paranoia, anxiety, etc.)  History or diagnosis of schizophrenia, bipolar or a psychotic disorder  History of any mental health illness that in the opinion of the Investigator would compromise the safety of the participant  Current or historical severe depression  Current suicidal ideation  Diagnosed cognitive impairment (e.g. Alzheimer's Disease, traumatic brain injury)  Uncontrolled hypertension (>139/89)  Abnormal values on CBC (complete blood count) or CMP (comprehensive metabolic panel) laboratory analysis that are deemed clinically significant by study physician  Known hepatic disease or dysfunction, or identification of such on screening laboratory studies  Known cardiovascular disease  Abnormal result on electrocardiogram (ECG) that is deemed clinically significant by study MD  Cognitive disability that interferes with ability to provide consent or understand study procedure  History of seizure disorder  Diagnosed autoimmune or rheumatological disease such as rheumatoid arthritis (RA) or multiple sclerosis (MS)  Inability to refrain from using tobacco for at least 4 hours  Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data  Pending legal action or workers compensation  Pregnant females or females intending to become pregnant during the study period  Unwilling to use one of the accepted forms of contraception during the study period and for at least 60 days after completion of the study (females of childbearing potential and males with sexual partners of childbearing potential)  Lactating females  Analgesia Arm Exclusion Criteria:  Unwilling/unable to discontinue current opioid use for 14 days prior to Baseline study visit and throughout the study  Reduction Arm Exclusion Criteria:  Not interested in reducing or discontinuing use of prescribed opioids for chronic pain  Unwilling to allow the study team to communicate with the participant's opioid prescribing provider  *Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.